Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Low-Dose Oral Film Reduces Mental Disorder Agitation

Depression

Interim results from a clinical trial show a drug given as a dissolvable oral film in a lower dose reduces agitation in people with bipolar disorder and schizophrenia. . . . → Read More: Low-Dose Oral Film Reduces Mental Disorder Agitation

Brain-Computer Device Company Gains $33M in Early Funds

Electrode microarray illustration

A company creating brain-computer interface devices to help people with disabling communications impairments is raising $33 million in its first venture round. . . . → Read More: Brain-Computer Device Company Gains $33M in Early Funds

Real World Evidence Shown to Emulate Some Clinical Trials

Data pointing finger

A study of insurance claims records matching the design of randomized clinical trials shows claims data can in some cases resemble clinical trial results to make causal inferences. . . . → Read More: Real World Evidence Shown to Emulate Some Clinical Trials

Biotech Gains $53.7M Infectious Disease Test Award

SARS-Cov-2 virus

A maker of diagnostics for infectious diseases is receiving a $53.7 million contract to develop and validate reliable home molecular tests for Covid-19 and flu infections. . . . → Read More: Biotech Gains $53.7M Infectious Disease Test Award

Biotech Group Blasts Reproductive Drug Ruling

Mifeprex boxes

A biotechnology industry group calls Friday’s ruling in a Federal district court to suspend approval of the drug mifepristone “an assault on science.” . . . → Read More: Biotech Group Blasts Reproductive Drug Ruling

Trial Okayed for Glaucoma Treatment Implant

Fundus photograph

A developer of treatments for eye diseases says it received clearance from FDA to begin a clinical trial of a sustained-release implant therapy for glaucoma. . . . → Read More: Trial Okayed for Glaucoma Treatment Implant

Trial to Test Low-Dose Psilocybin for Mental Distress

Psilocybe aztecorum

A developer of mental health therapies from psychedelic compounds says it received FDA clearance for a clinical trial testing low doses of psilocybin. . . . → Read More: Trial to Test Low-Dose Psilocybin for Mental Distress

Standard Electronic Biomarkers Validated for Schizophrenia

Brain cell networks

A new study validates standard electronic instrument measures of healthy individuals and people with schizophrenia to enable reliable clinical trials for treating the disease. . . . → Read More: Standard Electronic Biomarkers Validated for Schizophrenia

RSV Vaccine Breakthrough Examined at AAAS Meeting

Barney Graham at AAAS, 5 Mar 2023

As three vaccines against respiratory syncytial virus reach FDA review, a scientific conference explored a key breakthrough researchers achieved to get to this point. . . . → Read More: RSV Vaccine Breakthrough Examined at AAAS Meeting

Panel: A.I. Regulation Needed, But Long Way Off

Emma Pierson at AAAS meeting

A panel of data scientists at a professional meeting says artificial intelligence needs more rigorous oversight, but many questions remain on who and how to do the regulating. . . . → Read More: Panel: A.I. Regulation Needed, But Long Way Off